Abelacimab, formerly known as MAA868, represents a novel approach to managing thrombosis. This blood-thinning agent is a targeted monoclonal immunoglobulin that prevents the integrin αIIbβ3, a key player in platelet https://www.targetmol.com/compound/abelacimab